biomarker Archives -

Nicolas Vachicouras, CEO of Neurosoft Bioelectronics, tells us how Neurosoft’s electrode implant aims to reduce inflammation and scar

The transformation of brain implants

https://pharmaphorum.com/r-d/the-transformation-of-brain-implants/

Digital/ News/ News

How’s my driving? GPS tracking spots Alzheimer’s with 86% accuracy

Phil Taylor Alzheimer's disease, biomarker, digital, digital health, neurology 0 Comment

Diagnosing Alzheimer’s disease is still a challenge, particularly in its earliest stages, but a new study suggests that

How’s my driving? GPS tracking spots Alzheimer’s with 86% accuracy

https://pharmaphorum.com/news/hows-my-driving-gps-tracking-spots-alzheimers-with-86-accuracy/

Digital/ News/ News

physIQ licenses virtual trial tech to Janssen in multi-year deal

Richard Staines biomarker, digital, Janssen, physIQ, virtual trials 0 Comment

Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal,

physIQ licenses virtual trial tech to Janssen in multi-year deal

https://pharmaphorum.com/news/physiq-licenses-virtual-trial-tech-to-janssen-in-multi-year-deal/

News/ News/ Oncology

Limited access to cancer biomarker testing in Europe, report finds

Richard Staines biomarker, cancer, EFPIA, patients 0 Comment

There is limited access to biomarker testing for cancer in Europe, despite the huge potential of the technology

Limited access to cancer biomarker testing in Europe, report finds

https://pharmaphorum.com/news/limited-access-to-biomarker-testing-in-europe-report-finds/

Digital/ News/ News

AI startup Nucleai has immuno-oncology treatment failures in its sights

Phil Taylor artificial intelligence, biomarker, breast cancer, immuno-oncology, Nucleai, Oncology, spatial biology 0 Comment

Israeli company Nucleai is putting artificial intelligence to work to discover why so many cancer patients don’t respond

AI startup Nucleai has immuno-oncology treatment failures in its sights

https://pharmaphorum.com/news/ai-startup-nucleai-has-immuno-oncology-treatment-failures-in-its-sights/

News/ News/ Oncology

Merck & Co’s Keytruda approved for second “tumour agnostic” use

Richard Staines biomarker, cancer, Keytruda, Merck & Co, Oncology 0 Comment

Merck & Co’s Keytruda cancer immunotherapy has been approved by the FDA in another “tumour agnostic” use, in

Merck & Co’s Keytruda approved for second “tumour agnostic” use

https://pharmaphorum.com/news/merck-cos-keytruda-approved-for-second-tumour-agnostic-use/

Events/ Events/ R&D

4th Microbiome Movement – Drug Development Europe Summit

jenna.warren@hansonwade.com biomarker, diagnostic, drug development, microbiome, therapeutic

Microbiome Movement – Drug Development Europe Summit

4th Microbiome Movement – Drug Development Europe Summit

https://pharmaphorum.com/events/4th-microbiome-movement-drug-development-europe-summit/

Partner content/ Press releases

Mike Page, Alexion Pharmaceuticals invite to SMi’s Orphan Drugs & Rare Diseases

ssapal@smi-online.co.uk artificial intelligence, biomarker, orphan drugs, patient access, Rare diseases 0 Comment

Mike Page, invite to Orphan Drugs & Rare Diseases

Mike Page, Alexion Pharmaceuticals invite to SMi’s Orphan Drugs & Rare Diseases

https://pharmaphorum.com/partner-content/mike-page-alexion-pharmaceuticals-invite-to-smis-orphan-drugs-rare-diseases/

Events/ Events/ Healthcare

Global Biobanking Congress

katebarlow@globalengage.co.uk Biobanking, bioinformatics, biomarker, biospecimen, cryogenics 0 Comment

Event

Global Biobanking Congress

https://pharmaphorum.com/events/global-biobanking-congress/

Trending

biomarker

Login